Target intelligence / Profile preview

Choriogonadotropin subunit beta (beta-hCG)

Target
beta-hCG
Molecular classification
Glycoprotein hormone, Hormone subunit, Other (not a classical receptor/enzyme/transporter)
01

Overview

Choriogonadotropin subunit beta (beta-hCG) is the unique beta subunit of the human chorionic gonadotropin hormone, distinguishable from other glycoprotein hormone beta subunits by its sequence and glycosylation. It is encoded by six highly homologous genes on chromosome 19q13.3 and comprises 145–165 amino acids with extensive glycosylation and multiple disulfide bonds. The beta subunit confers biological specificity, driving receptor binding and subsequent signal transduction. In early pregnancy, it is secreted by the syncytiotrophoblast and maintains the corpus luteum, allowing sustained progesterone production that is crucial for endometrial maintenance. As a biomarker, beta-hCG is widely measured for pregnancy detection and in oncology for identifying certain tumors. Exogenous or recombinant beta-hCG is used clinically for inducing ovulation and supporting assisted reproductive procedures.

Other names
Human chorionic gonadotropin beta subunitBeta-hCGhCG-betaCGBChoriogonadotropin chain betaCG-beta
02

Mechanism of action

Mimics luteinizing hormone (LH) to stimulate LH/hCG receptor Promotes ovulation in infertility therapy Stimulates testosterone production in males Maintains corpus luteum for progesterone production

03

Biological functions

Signal transduction (via LH/hCG receptor)Maintenance of pregnancy (maternal recognition)Steroidogenesis stimulationCell proliferationCell differentiationInduction of immunotoleranceApoptosis regulation
04

Disease associations

Cancer (tumor marker for germ cell tumors, choriocarcinoma, other cancers)Pregnancy complications (abnormal levels indicate trophoblastic disease, gestational trophoblastic neoplasia, etc.)Other (male hypogonadism, infertility treatment)
05

Safety considerations

Ovarian hyperstimulation syndrome (therapeutic use)False positives in cancer screeningRisk of overdosage in fertility therapy
06

Interacting drugs

Exogenous hCG preparations (Pregnyl, Profasi, Novarel, Ovidrel, etc.)

1 more in the full profile.

07

Biomarkers

Beta-hCG serum and urine levels (pregnancy detection, monitoring of pregnancy viability)Beta-hCG as tumor marker (germ cell tumors, choriocarcinoma)

Beyond the preview

Go deeper on Choriogonadotropin subunit beta (beta-hCG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Choriogonadotropin subunit beta (beta-hCG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call